NCT04213261View on ClinicalTrials.gov

A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

June 9, 2020

Primary Completion Date

January 17, 2023

Study Completion Date

July 31, 2037

Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
BIOLOGICAL

FCX-007 (dabocemagene autoficel; see below for FCX-007 description)

FCX-007 is comprised of fibroblasts isolated from the subject's skin biopsies which are genetically corrected with the full length COL7A1 gene encoding for type VII collagen.

Trial Locations (5)

32256

Solutions Through Advanced Research, Inc., Jacksonville

55905

Mayo Clinic, Rochester

78723

Dell Children's Medical Group, Austin

80045

Children's Hospital Colorado, Aurora

94305

Stanford University, Stanford

Sponsors
All Listed Sponsors
lead

Castle Creek Biosciences, LLC.

INDUSTRY